Business 30 September 2026 Daily Monitor (Uganda)
Quality Chemical to Manufacture Influenza Drugs Following Sub-Licence Deal
Quality Chemical Industries (QCI) has obtained a crucial sub-licence from the Medicines Patent Pool (MPP), paving the way for the local production of influenza medicines. This agreement is set to significantly boost QCI's manufacturing capabilities and access to essential drugs within Uganda and the wider African region. Source: https://www.monitor.co.ug/uganda/business/markets/quality-chemical-expands-drug-manufacturing-with-influenza-sub-licence--5614836
Quality Chemical Industries (QCI), a prominent pharmaceutical manufacturer in Uganda, has announced a significant expansion of its drug production capabilities. The company has secured a sub-licence from the Medicines Patent Pool (MPP), a United Nations-backed initiative, enabling it to develop and manufacture influenza medicines.
This strategic partnership will allow QCI to produce generic versions of critical influenza treatments, enhancing access to these vital drugs for Ugandans and potentially for distribution across the African continent. The agreement is a landmark achievement for QCI, demonstrating its commitment to strengthening local pharmaceutical manufacturing and contributing to public health security.
By obtaining this sub-licence, QCI gains the rights to manufacture specific influenza antiviral medications. This development is expected to reduce reliance on imported drugs, potentially lowering costs and ensuring a more stable supply chain for essential medicines. The move aligns with global efforts to improve pandemic preparedness and response, particularly in low- and middle-income countries.
The MPP plays a vital role in facilitating access to essential medicines by negotiating voluntary licences with pharmaceutical patent holders, allowing generic manufacturers to produce affordable versions. QCI’s involvement signifies a major step forward in building pharmaceutical self-sufficiency within Uganda and the East African region.
This expansion is anticipated to create new employment opportunities within QCI and foster further growth in Uganda’s pharmaceutical sector. The company’s enhanced manufacturing capacity will be instrumental in addressing current and future health challenges, including potential influenza outbreaks. The agreement underscores the importance of collaboration between international organizations and local industries to improve healthcare outcomes.